



**SafeBiologics**  
ALLIANCE *for* SAFE BIOLOGIC MEDICINES

**GaBi**  
GENERICS AND BIOSIMILARS INITIATIVE  
*Building trust in cost-effective treatments*

# ASBM/GaBI 2022 Biosimilars Webinar Series

## **NON-MEDICAL SWITCHING OF BIOLOGICALS/BIOSIMILARS: CANADA, EUROPE AND THE US**

*Overview of non-medical switching practices in different regions and  
the importance of safeguarding the physician–patient relationship*

### **Summary of Registrants/Attendees Profile**



**SafeBiologics**  
ALLIANCE for SAFE BIOLOGIC MEDICINES

**GaBi**

GENERICS AND BIOSIMILARS INITIATIVE  
*Building trust in cost-effective treatments*

Second Webinar – 20 July 2022

# NON-MEDICAL SWITCHING OF BIOLOGICALS/BIOSIMILARS: CANADA, EUROPE AND THE US

**Overview of Non-Medical Switching Practices of Biologicals/  
Biosimilars in Different Regions and the Importance of  
Safeguarding the Physician–Patient Relationship**

Wednesday, 20 July 2022 | 10:00 am – 12:00 pm (EDT)



This public webinar  
is hosted by



**SafeBiologics**  
ALLIANCE for SAFE BIOLOGIC MEDICINES

**GaBi**

GENERICS AND BIOSIMILARS INITIATIVE  
*Building trust in cost-effective treatments*

**Watch Replay**



# About ASBM/GaBI 2nd Webinar Registrants

## **No. of registrants**

257<sup>§</sup> (speakers included) registered for the SafeBiologics/GaBI webinar on:

**NON-MEDICAL SWITCHING OF BIOLOGICALS/BIOSIMILARS: CANADA, EUROPE AND THE US**

**No. of countries registered/attended: 59 / 38**

**Top 10 countries** represent 71% of the total attendees


**Attendance rate** at 50%\* (16.3% higher than the first webinar)

**Areas of interests: 21**

<sup>§</sup>5.3% higher than the first webinar; \*average webinar attendance rate: 40%



# Registrants by Areas of Interests



Nine (9) areas of interests represents 51.4% of total registrants



## Registrants by Areas of Interests (cont'd)

Registrants are diverse from the following areas of interests:

### Group A (51.4%)

Academic; Association/Society; Government/Non-profit; Healthcare Professional, e.g. nurses, pharmacists, physicians; Hospital; Institute; Insurance company; Patient; Regulatory agency


### Group B (48.6%)

Biotechnology/Biopharmaceuticals, Clinical Research Organisation, Consulting, Finance, Generics/Biosimilars manufacturer, Information provider, Legal, Manufacturer of chemicals/raw materials (API), Media, Other, Pharmaceutical companies, Service/Supply/Manufacturing

N = 21



## Attendees by Geographic Zones



**Latin American countries (7%) are included in Zone Americas**

RoW: Rest of World



## NON-MEDICAL SWITCHING OF BIOLOGICALS/BIOSIMILARS: CANADA, EUROPE AND THE US

### Top 10 Countries of Webinar Attendees

USA	Canada	Philippines	Belgium	India
France	Switzerland	Brazil	Cyprus/Spain	South Africa



## NON-MEDICAL SWITCHING OF BIOLOGICALS/BIOSIMILARS: CANADA, EUROPE AND THE US

### Top 5 Countries of Attendees per Geographic Zone

Americas	Europe	Asia	Middle East	Africa
USA/Canada	France	Philippines	Saudi Arabia	South Africa
Brazil	Switzerland	India	UAE	Kenya
Argentina	Spain	Malaysia	Israel	Cameroon
Mexico	Germany	Korea/Taiwan	Turkey	--
Chile/Costa Rica	UK	Thailand	Iraq	--





# NON-MEDICAL SWITCHING OF BIOLOGICALS/BIOSIMILARS: CANADA, EUROPE AND THE US

Wednesday, 20 July 2022 | 10:00 am – 12:00 pm (EDT)

Overview of Non-Medical Switching Practices of Biologicals/Biosimilars in Different Regions and the Importance of Safeguarding the Physician–Patient Relationship

## FULL SPEAKERS FACULTY & PANELISTS



**Michael S Reilly, Esq**  
Executive Director  
Alliance for Safe Biologic Medicines  
USA



**Gail Attara**  
President & CEO  
Gastrointestinal Society  
Canada



**Ralph McKibbin**  
MD, FACP, FACG, AGAF  
President of the Pennsylvania Society of Gastroenterology and the Digestive Disease National Coalition  
USA



**Leah Christl, PhD**  
Executive Director  
Global Regulatory and R&D Policy, Amgen  
USA



**Durhane Wong-Rieger, PhD**  
President & CEO  
Canadian Organization for Rare Disorders  
Canada



**Professor Philip J Schneider**  
MS, FASHP, FASPEN, FFIP  
Professor at The Ohio State University College of Pharmacy  
USA



**Steven Stranne, MD**  
JD Partner, Foley Hoag LLP  
USA  
**Moderator**



**Jaymee Maaghob**  
Outreach Coordinator  
Gastrointestinal Society  
Canada  
**Panelist**



**Urvashi Rathod**  
Project Officer  
International Federation on Ageing, Canada  
**Panelist**

# GaBi

GENERICS AND BIOSIMILARS INITIATIVE

*Building trust in cost-effective treatments*

Speakers' presentations available for [download](#)

[Watch](#) replay of the webinar:

<https://youtu.be/A5nJkCJM32M>



Thank you for your attendance to the joint ASBM/GaBI webinar



[WATCH REPLAY](#) of the ASBM/GaBI 1st Webinar on  
**KEY FACTORS FOR SUCCESSFUL UPTAKE OF BIOSIMILARS:  
EUROPE AND THE US**

Wednesday, 29 June 2022 | 10:00 am – 12:00 pm (EDT)

**DON'T MISS OUT!**



**SafeBiologics**  
ALLIANCE for SAFE BIOLOGIC MEDICINES

**GaBi**

GENERICS AND BIOSIMILARS INITIATIVE  
*Building trust in cost-effective treatments*

**NEW KEYNOTE SPEAKER**

**Measures Taken for Improving Biosimilar Uptake and the Potential Role of Healthcare Providers and Patients**

**Wednesday, 29 June 2022 | 10:00 – 12:00 (EDT)**

**Watch Replay**



This public webinar is hosted by



**SafeBiologics**  
ALLIANCE for SAFE BIOLOGIC MEDICINES

**GaBi**

GENERICS AND BIOSIMILARS INITIATIVE  
*Building trust in cost-effective treatments*



Thank you for your attendance to the joint ASBM/GaBI webinar



The discussion will continue at the next webinar on  
**'Ophthalmic Biosimilars'** in September 2022.

More information will be available soon or  
contact us at [editorial@gabi-journal.net](mailto:editorial@gabi-journal.net) for more information!

**DON'T MISS OUT!**



**SafeBiologics**  
ALLIANCE *for* SAFE BIOLOGIC MEDICINES

**GaBi**  
GENERICS AND BIOSIMILARS INITIATIVE  
*Building trust in cost-effective treatments*

# Thank you!

Lasia Tang

- Publisher, GaBI Online, GaBI Journal
- Director and Organiser, GaBI Educational Forum
- Co-Founder, GaBI (Generics and Biosimilars Initiative)
- Executive Director, GaBI IVZW

Contact:

Tel: +32 474 989 572

Email: [LTang@gabionline.net](mailto:LTang@gabionline.net)